Sequella, Inc.

Sequella, Inc. is a clinical-stage pharmaceutical company dedicated to combating antibiotic-resistant bacterial diseases through the discovery, development, and commercialization of innovative antibiotics with novel mechanisms of action. Sequella's commitment to addressing global health threats is evident in its robust product portfolio, which targets diseases with known or suspected infectious etiologies.

Sequella, Inc. is focused on advancing its lead drug candidate, SQ109, currently in Phase 2 clinical trials for the treatment of tuberculosis (TB) and gastritis (Helicobacter pylori infections). Recognizing the growing resistance to existing drugs, Sequella acquired sutezolid, a Phase 2 oxazolidinone, to further strengthen its TB treatment capabilities. In addition to its clinical-stage assets, Sequella maintains a vigorous research program to develop novel antibiotics that target the enzyme translocase-1, an essential enzyme in all bacteria. Sequella, Inc. is located at 9610 Medical Center Drive, Suite 200, Rockville, Maryland 20850, US.

Sequella, Inc.'s diverse product portfolio addresses significant market opportunities in areas such as tuberculosis, duodenal ulcers, gastric carcinomas, CDI (Clostridium difficile), Crohn’s Disease, and Chagas Disease. Management will soon be providing additional details about these programs. We invite the manager of Sequella, Inc. to create a customized and exclusive company showcase and product listing on our platform to further highlight their groundbreaking work.